Tiftikci Arzu, Ozdemir Ali, Tarcin Ozlem, Tarcin Orhan, Inanc Nevsun, Sahinoglu Sureyya, Direskeneli Haner, Yavuz Sule, Uras Fikriye, Barut Yildiz
Internal Medicine Department, Haydarpasa Numune Hospital, Istanbul, Turkey.
Rheumatol Int. 2006 Jan;26(3):191-4. doi: 10.1007/s00296-004-0546-x. Epub 2005 Jan 12.
The purpose of this study was to investigate whether negative effects of methotrexate (mtx) on blood homocysteine (hmc) levels can be prevented with the replacement of folic acid. 42 female patients with rheumatoid arthritis (RA) were studied. Patients were separated into two groups according to their treatment status with mtx (group I: 27 patients taking mtx and folic acid; group II: 15 patients not using mtx). The level of hmc was found to be 6.3+/-2.4 micromol/l in group I and 7.87+/-3.2 micromol/l in group II (p>0.05). Folic acid levels of group I and II were found to be 21.3+/-15.9 ng/ml and 8.41+/-2.86 ng/ml respectively (p<0.001). There was a statistically-significant correlation between age and hmc levels (r=0.386, p=0.012). Negative statistically-significant correlations were observed between folic acid and hmc levels. The effects of mtx on hmc can be prevented with the replacement of folic acid.